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Abstract
The mechanisms by which microvascular damage leads to
dermal fibrosis in diffuse cutaneous systemic sclerosis (dcSSc)
are unclear. We hypothesized that microvascular pericytes
constitute a cellular link between microvascular damage and
fibrosis by transdifferentiating into myofibroblasts. We used a
combination of immunohistochemistry and double
immunofluorescence labelling of frozen skin biopsies taken from
normal and dcSSc patients to determine whether a phenotypic
link between pericytes and myofibroblasts exists in dcSSc.
Using  α -smooth muscle actin, the ED-A splice variant of
fibronectin (ED-A FN) and Thy-1 to identify myofibroblasts, we
demonstrated the presence of myofibroblasts in fibrotic dcSSc
skin. Myofibroblasts were totally absent from control skin,
atrophic stage dcSSc skin and non-lesional skin. Using double
immunofluorescence labelling, both myofibroblasts and
pericytes were shown to express ED-A FN and Thy-1 in dcSSc
skin but not in control skin. Proliferating cell nuclear antigen was
also expressed by myofibroblasts and pericytes in dcSSc skin
while being absent in control skin. These observations suggest
that the presence of myofibroblasts may represent a transitional
phase during the fibrotic stages of dcSSc and that Thy-1+ve
pericytes participate in the fibrogenic development of dcSSc by
synthesizing ED-A FN, which may be associated with a
proliferation and transition of pericytes and fibroblasts to
myofibroblasts, thus linking microvascular damage and fibrosis.
Introduction
Systemic sclerosis represents a spectrum of connective tissue
disorders, characterized by chronic and debilitating fibrosis of
the skin and internal organs, most notably the lungs, kidney,
cardiovascular system and gastrointestinal tract [1]. While the
pathological endpoint of diffuse cutaneous systemic sclerosis
(dcSSc) is recognized as clinical fibrosis, the origins are
thought to lie in the microvasculature, as over 90% of patients
exhibit chronic microvascular damage prior to the onset of clin-
ical fibrosis [2]. Beyond that, however, very little is known
about the cellular and molecular mechanisms that produce
chronic fibrotic lesions in dcSSc. Microvessels comprise two
cell types, endothelial cells and pericytes. Analyses of microv-
ascular changes in dcSSc have focussed almost solely on the
contribution of endothelial cells, largely overlooking the poten-
tial role of pericytes. Pericytes reside at the abluminal surface
of microvessels and are in intimate contact with the underlying
endothelium through numerous points of cell-cell contact. It
has become increasingly clear that pericytes are vital in main-
taining normal vascular homeostasis and regulating vascular
phenotype in disease [3]. Given their central role in modulating
endothelial cell function, it is clear that the pronounced
changes observed in endothelial cells during dcSSc will also
alter pericyte phenotype and function. Consistent with this
idea, we have previously demonstrated that microvascular per-
icytes become activated and express platelet-derived growth
factor-beta (PDGF-β ) receptors in dcSSc, a phenotype not
seen in normal skin [4].
α -SMA = alpha smooth muscle actin; DAPI = 4,6-diamidino-2-phenylindole; dcSSc = diffuse cutaneous systemic sclerosis; ED-A FN = ED-A 
fibronectin; FITC = fluorescein isothiocyanate; LOX = lysyl oxidase; PBS = phosphate buffered saline; PCNA = proliferating cell nuclear antigen; 
PDGF = platelet-derived growth factor; RNP = ribonuclear protein; TGF-β  = transforming growth factor-beta.Arthritis Research & Therapy    Vol 7 No 5    Rajkumar et al.
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Of potential significance in fibrotic diseases is the phenotypic
similarity between pericytes and myofibroblasts. Like peri-
cytes, myofibroblasts express alpha smooth muscle actin (α -
SMA) and are strongly associated with fibrotic tissue [5]. Orig-
inally described in wound tissue, the primary role of myofibrob-
lasts is contraction of early granulation tissue [6]. After wound
contraction, myofibroblasts are believed to be removed by
apoptosis, a crucial step in wound resolution [7]. Failure of the
local myofibroblast population to undergo apoptosis has been
postulated as a mechanism whereby an acute wound
response can become a chronic fibrotic disorder [8]. Differen-
tiated myofibroblasts can be distinguished from normal fibrob-
lasts by the expression of α -SMA and the ED-A splice variant
of fibronectin (ED-A FN). ED-A FN expression precedes the
appearance of α -SMA-positive myofibroblasts and is consid-
ered a crucial factor in promoting the formation of myofibrob-
lasts [9]. Blocking the interaction between ED-A FN and the
cell surface in vitro inhibits the transforming growth factor-
beta (TGF-β )-mediated induction of α -SMA synthesis and
resultant myofibroblast formation. Thus, the de novo synthesis
of ED-A FN appears to be a pre-requisite of α -SMA expression
and myofibroblast differentiation [10]. Increased expression of
ED-A FN has been reported in other fibrotic disorders [11,12],
however, not in dcSSc. In common with practically all fibro-
contractive diseases, the presence of myofibroblasts has been
described in dcSSc skin [13,14], however, beyond that very
little is known about their precise role in the disease process.
For example, the mechanisms of their appearance and persist-
ence within fibrotic tissue remain unclear, as does their contri-
bution to increased matrix deposition.
Another factor implicated in the differentiation of myofibrob-
lasts is Thy-1, a cell surface glycoprotein, which is differentially
expressed by fibroblasts [15]. Thy-1+ve and Thy-1-ve popula-
tions of fibroblasts are known to be functionally distinct with
regards to production of cytokines and extracellular matrix
[16,17] and it was recently demonstrated that only Thy-1+ve
fibroblasts are capable of differentiating into myofibroblasts
after treatment with TGF-β  [18], suggesting that Thy-1 is a
marker of cells with myofibroblastic potential.
In liver fibrosis and glomerular fibrosis, pericytes have been
proposed as a source of myofibroblasts [19,20]. This hypoth-
esis is compatible with the clinical picture in dcSSc of chronic
microvascular damage followed by fibrosis. It is known that
pericytes have the capacity to act as precursor cells for other
differentiated mesenchymal cells [21], including collagen-syn-
thesizing fibroblasts [22,23]. Therefore, we hypothesized that
microvascular pericytes are precursor cells for myofibroblasts
in dcSSc skin. Using double immunofluorescence labelling,
we have been able to show that pericytes and myofibroblasts
share an identical phenotype with regards to α -SMA, ED-A FN
and Thy-1 in dcSSc skin.
Materials and methods
Patient and biopsy specimens
All patients in the study were diagnosed as having diffuse scle-
roderma (n = 16) using the classification established by LeRoy
et al. [24]. The SSc cohort included 10 patients with fibrotic
dcSSc and six patients with atrophic dcSSc. Following
informed consent and ethical approval, lesional skin was taken
from the forearms of patients with fibrotic scleroderma and
non-lesional skin was taken from the lower back. Non-lesional
skin was defined as having a modified Rodnan skin score of
zero. Site-matched normal skin samples were obtained from
sex- and age-matched volunteers (n = 8). Clinical characteris-
tics are presented in Table 1. Disease severity and internal
organ involvement was assessed according to the recently
published consensus for SSc studies [25]. Therefore, skin
involvement was assessed using the modified Rodnan skin
score and gastrointestinal involvement was defined sympto-
matically. A restrictive pattern of pulmonary function abnormal-
ities with reduction in forced vital capacity and diffusion
capacity for carbon monoxide below 80% of predicted value
(based on age, sex, height and ethnic origin) was used to
assess interstitial lung involvement. This was confirmed by
high-resolution computed tomography of the chest. Diagnosis
of pulmonary arterial hypertension was confirmed by right
heart catheterization. Cardiac involvement was considered
present if any significant conduction defects were found on
electrocardiogram or impaired left ventricular function, or if
haemodynamically significant pericardial effusion was
detected by echocardiography. A greater than four-fold eleva-
tion of creatinine kinase accompanied by the clinical finding of
proximal weakness defined muscular involvement, whilst renal
involvement was determined by history of scleroderma renal
crisis or significant impairment in creatinine clearance (<65
ml/min) without alternative explanation.
All biopsies were embedded in OCT (optimum cutting temper-
ature compound) and immediately snap frozen in isopentane
cooled by liquid nitrogen and subsequently stored at -70°C
prior to cryosectioning.
Antibodies
Microvascular pericytes were identified using 1A4 (Sigma,
UK), a mouse monoclonal antibody against α -SMA [26]. The
monoclonal antibody AS02 (Oncogene, UK) was used to
identify Thy-1 [27] and the PAL-E monoclonal antibody (Uden,
Holland) recognizes endothelial cells with high sensitivity and
specificity [28,29]. ED-A FN was identified using the 3E2
monoclonal IgM antibody (Sigma) [30] and a rabbit polyclonal
antibody recognizing lysyl oxidase (LOX) was used to identify
cells synthesizing collagen and elastin [31]. LOX plays a cen-
tral role in catalysing collagen cross-linking within the extracel-
lular matrix [32] and has been established as a surrogate
marker for collagen-synthesizing cells [33]. Proliferating cells
were labelled with a rabbit polyclonal antibody against prolifer-
ating cell nuclear antigen (PCNA) (Abcam, UK) [34].Available online http://arthritis-research.com/content/7/5/R1113
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Biotinylated secondary antibodies against mouse IgG and IgM
and Vectastain ABC reagent were obtained from Vector Lab-
oratories, (Peterborough, UK). All antibodies were diluted in
PBS.
Immunohistochemistry
Serial frozen sections (6 µm) were cut on a cryostat, air-dried
and then stored at 80°C prior to use. Sections were fixed in
ice-cold acetone and then blocked with normal horse serum
and incubated with primary antibodies for 1 h at room temper-
ature. Endogenous peroxidase was exhausted by incubation
with H2O2 at room temperature for 15 mins in the dark. After
washing, sections were incubated with the appropriate bioti-
nylated secondary antibody (7.5 µg/ml) diluted in PBS for 30
mins, rinsed and then finally incubated with Vectastain ABC
reagent for 30 mins (Vector Laboratories, Peterborough, UK).
After washing, sections were visualized using 3-amino-9-ethyl-
carbazole and then washed in tap water, counterstained with
haematoxylin and aqueously mounted with Crystal-Mount
(Biomeda, CA, USA). Sections were viewed and photo-
graphed on a Zeiss Axioskop 2 mot plus microscope. Controls
included an exchange of primary antibodies with isotype-
matched control antibodies.
Determination of PCNA-positive microvessels
In order to determine the proportion of microvessels express-
ing PCNA, serial cryosections were used. Briefly, serial cryo-
sections were treated as above and stained for PAL-E and
PCNA. Twenty fields of view were analysed using a ×20 Zeiss
Plan-Neofluar lens and results were expressed as a percent-
age of PAL-E-positive vessels.
Double immunofluorescence labelling
To investigate colocalization between cell-specific antigens,
double immunofluorescence labelling was carried out. Briefly,
cryosections were fixed in ice-cold acetone, blocked in serum
and incubated with the first primary antibody for 1 h, rinsed
and then incubated with the appropriate biotinylated second-
ary antibody (7.5 µg/ml) for 30 mins. Sections were rinsed and
incubated with Avidin Texas Red 25 µg/ml for 30 mins. After
Table 1
Clinical and serological characteristics of SSc patients
Characteristics Fibrotic (n = 10) Atrophic (n = 6)
Mean age (range) 54 (39–72) 58 (37–69)
Mean disease duration, months (range) 11 (4–18) 96 (36–168)
Male/female 2/8 0/6
Organ involvement
Mean skin score (range) 33 (19–41) 17 (11–24)
Oesophageal 7/10 3/6
Other gastrointestinal 4/10 1/6
Lung 4/10 2/6
Muscle 3/10 0/6
Renal 2/10 1/6
Cardiac 0/10 1/6
Pulmonary hypertension 2/10 0/6
Serology
Antinuclear 10/10 6/6
Anti-topoisomerase 1 4/10 3/6
Anti-RNA polymerase I/III 2/10 1/6
Anti-nuclear RNP 1/10 1/6
Microvascular damage
Structural capillary damage 10/10 6/6
RNP, ribonuclear protein; SSc, systemic sclerosis.Arthritis Research & Therapy    Vol 7 No 5    Rajkumar et al.
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blocking with serum, the sections were then incubated with
the second primary antibody for 1 h, rinsed and incubated with
an appropriate secondary IgG fluorescein (FITC) conjugate
(12.5 µg/ml) for 30 mins. Sections were finally counterstained
with 4,6-diamidino-2-phenylindole (DAPI) to visualize cell
nuclei. The sections were then mounted using Gel-Mount anti-
fade medium (Biomeda, CA, USA), and viewed using a Zeiss
Axioskop 2 mot plus microscope with Axiovision software.
Nailfold capillaroscopy
Nailfold capillaroscopy was performed using a Nikon optical
system illuminated by a fibre optic light source. Images were
analysed and recorded with a Hitachi CCD digital camera.
Microvascular damage was analysed and quantified using the
criteria established by Cutolo et al. Essentially, dcSSc patients
were graded as having an early (E), active (A) or late (L) pat-
tern of capillary damage [35].
Correlation of immunohistochemistry with clinical 
findings
Patients were classified according to four immunohistochemi-
cal criteria:
1. evidence of myofibroblasts/ED-A FN,
2. evidence of collagen synthesis,
3. evidence of myofibroblasts/ED-A FN and collagen
synthesis,
4. no evidence of either myofibroblasts/ED-A FN or collagen
synthesis.
Disease duration, skin score and capillary damage were com-
pared between groups. Statistical significance was deter-
mined by ANOVA and Fishers Exact test with p values <0.05
considered to be statistically significant.
Results
Myofibroblasts are present only in fibrotic dcSSc skin
The distribution of myofibroblasts was investigated using the
1A4 monoclonal antibody against α -SMA. In normal skin, α -
SMA immunostaining was predominantly restricted to microv-
ascular pericytes, sweat glands and smooth muscle cells of
the erector pili muscles (Fig. 1a). No α -SMA immunoreactivity
was detected in interstitial fibroblasts (Fig. 1a). Six dcSSc
cases were characterized by the presence of myofibroblasts
(Fig. 1b). In five of these cases, myofibroblasts were located
almost exclusively in the lower reticular dermis and were
absent from the upper papillary dermis where α -SMA immuno-
reactivity was restricted to microvascular pericytes (Fig. 1c). In
the remaining dcSSc case, myofibroblasts were detected in
both the reticular and papillary dermis (data not shown). In
reticular dermal areas containing myofibroblasts, α -SMA-
expressing cells were also frequently observed in the immedi-
ate perivascular area (Fig 1c,d) while in the papillary dermis, α -
SMA-expressing cells were only detected within the microvas-
cular wall (Fig. 1c). Myofibroblasts were not detected in any of
the non-lesional and atrophic dcSSc samples in which the pat-
tern of α -SMA immunostaining was similar to that seen in nor-
mal skin (Fig. 1e,f).
The presence of myofibroblasts correlates with the 
expression of ED-A FN but not collagen in dcSSc skin
Next we investigated whether myofibroblasts were associated
with the presence of ED-A FN and collagen in dcSSc skin.
Collagen-synthesizing cells were identified using an antibody
Figure 1
Detection of myofibroblasts in dcSSc skin Detection of myofibroblasts in dcSSc skin. Cryosections from (a) nor-
mal and (b-f) dcSSc skin were stained with an antibody against α -
SMA. In normal skin, α -SMA staining was restricted primarily to microv-
ascular pericytes enveloping capillaries ((a) arrows), sweat glands ((a) 
black arrowhead) and smooth muscle cells of erector pili muscles ((a) 
white arrowhead). In dcSSc samples, α -SMA-expressing myofibrob-
lasts were detected in the dermis ((b,c,d) black arrows). Myofibroblasts 
were predominantly detected in the lower reticular dermis of SSc skin 
((c,d) black arrows) while interstitial cells in the papillary dermis did not 
express α -SMA ((c,d) white arrows). In reticular dermal layers, α -SMA 
staining was also detected in the perivascular region ((c,d) black arrow-
heads) while in the papillary dermal layers α -SMA immunostaining was 
restricted to microvessels ((c) white arrowhead). In (e) non-lesional and 
(f) late stage dcSSc, the distribution of α -SMA was similar to that seen 
in normal skin. Original magnification (a,b,e,f) ×10, and (c,d) × 20. α -
SMA, alpha smooth muscle actin; dcSSc, diffuse cutaneous systemic 
sclerosis.Available online http://arthritis-research.com/content/7/5/R1113
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against the enzyme lysyl oxidase (LOX) as previously reported
[36,37]. In normal skin, expression of LOX was noted in cells
within the epidermis and associated with collagen and elastic
fibres in the dermis (Fig. 2a). In four dcSSc cases, an increase
in LOX immunostaining was observed when compared with
normal skin, principally in interstitial fibroblastic cells through-
out the dermis (Fig. 2c) and cells associated with the microv-
asculature (Fig. 2e). Two of these dcSSc cases were also
characterized by the presence of myofibroblasts. The distribu-
tion of LOX immunostaining in all atrophic dcSSc and non-
lesional dcSSc tissue was similar to that seen in normal skin
(data not shown).
The distribution of ED-A FN was then evaluated. Little or no
immunostaining for ED-A FN was detected in normal skin (Fig.
2b). However, in six dcSSc cases there was marked increase
in ED-A FN staining, predominantly in fibroblastic cells and
small capillaries (Fig. 2d,f). Significantly, increased ED-A FN
deposition was only observed in those dcSSc samples con-
taining myofibroblasts. ED-A FN is known to be a key mediator
in the differentiation of myofibroblasts and, to our knowledge,
this is the first report of increased ED-A FN in dcSSc skin. We
then used serial cryosections to confirm that the expression of
ED-A FN was localized to the presence of myofibroblasts.
Increased immunostaining for ED-A FN was located predomi-
nantly in the reticular dermis mirroring the distribution of myofi-
broblasts (Fig. 3a,b). Papillary dermal layers, which were
negative for myofibroblasts, contained little or no ED-A FN
expression (Fig. 3a,b). In the lower reticular dermis in dcSSc,
immunostaining for ED-A FN was also frequently observed
associated with microvessels enveloped by α -SMA-positive
pericytes (Fig. 3c,d).
Increased dermal staining of Thy-1 in fibrotic dcSSc skin
It was recently reported that myofibroblasts can only differen-
tiate from Thy-1-expressing fibroblasts [18], therefore we ana-
lysed Thy-1 expression in vivo in order to identify putative
sources of myofibroblasts. In normal skin, Thy-1 immunostain-
ing was located predominantly in the microvascular wall and
the immediate perivascular region (Fig. 4a,b). Occasional cells
Figure 2
Increased expression of LOX and ED-A FN in dcSSc skin Increased expression of LOX and ED-A FN in dcSSc skin. Cryosec-
tions of (a,b) normal skin are compared with (c-f) dcSSc skin. In normal 
skin, immunostaining for LOX was detected in epidermal cells ((a) 
arrow). In dcSSc skin, immunostaining for LOX was detected in fibrob-
last-like cells throughout the dermis ((c,e) arrows) and in cells of the 
microvascular wall ((e) arrowhead). Little or no expression of ED-A FN 
was detectable in (b) normal skin, however, ED-A FN immunostaining 
was markedly increased in dcSSc skin ((d,f) arrows). Immunostaining 
for ED-A FN was also detected in cells of the microvascular wall ((f) 
arrowhead). Original magnification (a-d) × 10 and (e,f) × 20. dcSSc, 
diffuse cutaneous systemic sclerosis; ED-A FN, ED-A splice variant of 
fibronectin; LOX, lysyl oxidase.
Figure 3
Expression of ED-A correlates specifically with myofibroblasts in dcSSc  skin Expression of ED-A correlates specifically with myofibroblasts in dcSSc 
skin. (a,c) Serial cryosections were stained with antibodies against ED-
A FN and (b,d) α -SMA. Both ED-A FN ((a,c) arrows) and α -SMA+ve 
myofibroblasts ((b,d) arrows) were predominant in the lower reticular 
dermis of dcSSc skin. Note the absence of ED-A FN ((a) white arrow) 
and α -SMA+ve myofibroblasts ((b) white arrow) in the papillary dermis. 
In addition, immunostaining for ED-A FN was also detected in the wall 
of microvessels ((c) inset, arrowheads) correspondingly containing α -
SMA-expressing pericytes ((d) inset, arrowheads). Original magnifica-
tion (a,b) × 10, (c,d) × 20, inset (c,d) × 40. α -SMA, alpha smooth mus-
cle actin; dcSSc, diffuse cutaneous systemic sclerosis; ED-A FN, ED-A 
splice variant of fibronectin.Arthritis Research & Therapy    Vol 7 No 5    Rajkumar et al.
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within the dermis were also positively stained in both the
papillary and reticular dermal layers (Fig. 4b). In agreement
with previous studies, no Thy-1 immunostaining was detected
in the keratinocyte layers of the epidermis [38]. In all samples
of dcSSc skin, there was a pronounced increase in Thy-1
staining throughout the dermis (Fig. 4c). In perivascular
regions, Thy-1 immunostaining was frequently less pro-
nounced than that observed in normal skin (Fig. 4d). All cases
of atrophic dcSSc skin and non-lesional dcSSc skin showed
a similar distribution of Thy-1 immunostaining to that observed
in normal skin (data not shown).
Microvascular pericytes express ED-A fibronectin and 
Thy-1 in dcSSc skin
As the observed immunostaining for Thy-1 was strongly asso-
ciated with microvessels, we hypothesized that it may be in
part attributable to expression by microvascular pericytes.
Using immunofluorescence, we performed multiple labelling
experiments of normal and dcSSc skin sections to simultane-
ously visualize endothelial cells, pericytes and Thy-1 immuno-
positive fibroblasts. Combinations of these markers are
depicted in Fig. 5, highlighting the spatial relationship between
Thy-1 immunofluorescence and the microvasculature. We and
others have previously demonstrated that immunofluores-
cence staining for α -SMA and PAL-E, while being closely
associated, do not colocalize, indicating that these markers
can be used to discriminate between pericytes and endothelial
cells [4,23]. When used in combination with the anti-endothe-
lial cell antibody, PAL-E, immunofluorescence for Thy-1 and
endothelial cells was separate and exclusive with no evidence
that Thy-1 expression colocalized to endothelial cells in either
normal or dcSSc skin (Fig. 5a,b). Conversely, Thy-1 immun-
ofluorescence showed a marked colocalization with α -SMA
expression by microvascular pericytes in normal (Fig. 5c) and
dcSSc skin samples (Fig. 5d) confirming that the perivascular
expression of Thy-1 could be attributed to pericytes. In normal
skin, Thy-1 immunofluorescence that did not colocalize with α -
SMA could also be detected immediately adjacent to small
microvessels (Fig. 5c). We then carried out double-labelling
experiments with antibodies against ED-A FN in combination
with specific cellular markers to identify the sources of ED-A
FN in SSc skin. Immunofluorescence for ED-A FN colocalized
with interstitial α -SMA immunofluorescence in the dermis,
confirming our serial immunohistochemical data that in dcSSc
skin, myofibroblasts synthesize ED-A FN (Fig. 5e). Immunoflu-
orescence for ED-A FN was found to colocalize with both Thy-
1 and α -SMA within the microvascular wall leading to the con-
clusion that pericytes synthesize ED-A FN in dcSSc skin (Fig.
5f,g,h).
Fibroblasts and pericytes show evidence of proliferation 
in dcSSc skin
In order to determine whether the appearance of myofibrob-
lasts was accompanied by cell proliferation, we used an anti-
body against PCNA to analyse the distribution of proliferating
cells in normal and dcSSc skin. In normal skin, PCNA immu-
nostaining was detected in epidermal cells and cells associ-
ated with hair follicles and sweat glands (Fig. 6a). Little or no
immunostaining for PCNA was seen in interstitial fibroblastic
cells or microvessels. Analysis of the dcSSc samples revealed
a marked expansion of PCNA immunostaining in two cases.
PCNA staining was detected in dermal fibroblast-like cells
(Fig. 6b) and was also evident within a proportion of microves-
sels (Fig. 6c). These two dcSSc samples were also character-
ized by the presence of myofibroblasts and increased ED-A
FN expression. Double-labelling analysis with combinations of
PCNA and α -SMA revealed colocalization between these pro-
teins in a proportion of microvessels (Fig. 6d,e) indicating per-
icyte proliferation. Colocalization was also observed between
PAL-E and PCNA (Fig. 6f). Serial sections stained with PCNA
and PAL-E revealed that 14% of PAL-E positive microvessels
showed evidence of PCNA immunostaining.
Correlation of immunohistochemistry with clinical 
findings
We then correlated our immunohistochemical findings with
clinical data (Table 2). Patients were classified according to
four immunohistochemical criteria, as listed in Materials and
methods.
Figure 4
Expression of Thy-1 is increased in dcSSc skin Expression of Thy-1 is increased in dcSSc skin. Cryosections from 
(a,b) normal and (c,d) dcSSc were stained for Thy-1 expression. In nor-
mal skin, immunostaining for Thy-1 was predominantly located within 
the microvascular wall and immediate perivascular region ((a,b) arrows). 
Thy-1 staining of interstitial fibroblasts was also detected ((b) arrow-
head). In dcSSc skin, immunostaining of fibroblastic cells was consider-
ably more pronounced throughout the interstitial dermis ((c) arrows) 
while perivascular immunostaining in dcSSc skin ((d) arrow) was less 
pronounced than that observed in normal skin ((b) arrow). dcSSc, dif-
fuse cutaneous systemic sclerosis.Available online http://arthritis-research.com/content/7/5/R1113
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No significant association was found between mean disease
duration (p = 0.11) and skin score (p = 0.97) and our immu-
nohistochemical groups. We were able to assess the capillary
patterns of eight of our ten dcSSc patients according to the
criteria established by Cutolo et al. [35]. Of these eight
patients, three had an active pattern of capillary damage while
five displayed a late pattern of damage (Fig. 7). However, no
significant association could be found between patterns of
capillary damage and our immunohistochemical groups (p =
0.33).
Discussion
The potential of pericytes as myofibroblast precursors in
dcSSc merits investigation for a number of reasons. Firstly, a
number of studies have highlighted the in vitro and in vivo
capacity of pericytes to act as mesenchymal precursor cells
[19,21,22,39]. Secondly, during liver and renal fibrosis, resi-
dent pericytes have been shown to differentiate into myofi-
broblasts. Finally, myofibroblasts have been previously
reported in dcSSc skin [13,14], however, their function and
origin remain unknown. The objective of our study was to
investigate both the origin and biosynthetic profile of myofi-
broblasts in dcSSc.
In our current study, myofibroblasts were detected in dcSSc
samples but were absent from normal skin. Correspondingly,
increased expression of ED-A FN was detected only in those
dcSSc samples containing myofibroblasts. Double-labelling
experiments confirmed the expression of ED-A FN to intersti-
tial myofibroblasts. To our knowledge, this is the first report of
ED-A FN expression by myofibroblasts in dcSSc skin. ED-A
FN was also found to be expressed by pericytes in the micro-
vascular wall of dcSSc skin using double-labelling with α -
SMA. Therefore, both myofibroblasts and pericytes appear to
be key sources of ED-A FN in dcSSc skin. As ED-A FN is a
pre-requisite for myofibroblast formation [9], the expression of
ED-A FN by pericytes is likely to be of significance in the dif-
ferentiation of perivascular fibroblasts and pericytes into myofi-
broblasts, and may represent a key step in linking
microvascular damage and fibrosis.
An assessment of our immunohistochemical findings and clin-
ical data revealed that the presence of myofibroblasts showed
no significant association with either disease duration (p =
0.11) or skin score (p = 0.97). Additionally, no association was
observed between the presence of myofibroblasts and either
late or active capillary damage (p = 0.33). While our prelimi-
nary findings are based on a relatively small cohort of patients,
we feel that further studies with a larger cohort of patients,
designed to correlate immunohistochemical findings with clin-
ical data on a patient-by-patient basis, may be highly
informative.
Myofibroblasts and ED-A FN were found almost exclusively in
the lower reticular dermis. A similar distribution of total
Figure 5
Double immunofluorescence labelling of normal and dcSSc skin  biopsies Double immunofluorescence labelling of normal and dcSSc skin biop-
sies. Cryosections from (a,c) normal and (b,d) dcSSc were double 
stained for endothelial cells using (a,b) PAL-E antibody and Thy-1 and 
(c,d) α -SMA and Thy-1. Thy-1 is labelled with FITC while PAL-E and α -
SMA are labelled with Texas Red. In both (a) normal and (b) dcSSc, 
immunofluorescence for Thy-1 ((a,b) arrow, green colour) and PAL-E 
((a,b) arrowhead, red colour) was consistently exclusive and showed no 
colocalization. In both (c) normal and (d) dcSSc, strong colocalization 
between Thy-1 and α -SMA was evident ((c,d) arrows, yellow colour). In 
normal skin, Thy-1 immunofluorescence that did not colocalize with α -
SMA was observed immediately adjacent to microvessels ((c) arrow-
heads, green colour). Cryosections from dcSSc were double stained 
for (e,f,g) ED-A FN and α -SMA and (h) ED-A FN and Thy-1. ED-A FN is 
labelled with Texas Red while α -SMA and Thy-1 are labelled with FITC. 
Cell nuclei are counterstained blue with DAPI. Colocalization between 
α -SMA and ED-A FN was detected in dermal fibroblastic cells ((e) 
arrows, yellow colour) as well as in the microvascular wall ((f,g) arrows, 
yellow colour). Colocalization was also observed between ED-A FN and 
Thy-1 in both the microvascular wall ((h) arrow, yellow colour) and in 
dermal fibroblastic cells ((h) arrowheads, yellow colour). Original magni-
fication (a-d,h) × 10, (e,f) × 20, (g) × 40. α -SMA, alpha smooth muscle 
actin; DAPI, 4,6-diamidino-2-phenylindole; dcSSc, diffuse cutaneous 
systemic sclerosis; ED-A FN, ED-A splice variant of fibronectin; FITC, 
fluorescein isothiocyanate.Arthritis Research & Therapy    Vol 7 No 5    Rajkumar et al.
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fibronectin has also been observed in dcSSc skin [40]. The
significance of this is unclear, however, it may reflect microen-
vironmental differences between the papillary and reticular
dermis or the existence of heterogeneous fibroblast popula-
tions within the respective dermal compartments, or a combi-
nation of both these factors. Interestingly, it has been
previously reported that reticular dermal fibroblasts are more
inherently contractile in three-dimensional collagen matrices
when compared with papillary dermal fibroblasts [41].
Our finding of myofibroblasts in six out of ten dcSSc patients
contrasts slightly with two previous studies in which all dcSSc
samples analysed contained myofibroblasts [13,14].
Discrepancies of this nature are unsurprising given the inher-
ent heterogeneity across the scleroderma spectrum, differ-
ences in the staining protocols and the cross-sectional nature
of these studies. However, it is worth reiterating that clear evi-
dence of increased matrix biosynthesis was detected in eight
out of ten dcSSc samples studied. Interestingly, only two
Figure 6
Distribution of proliferating cells in normal and dcSSc skin Distribution of proliferating cells in normal and dcSSc skin. Cryosections from (a) normal and (b,c) dcSSc were stained with an anti-PCNA antibody. 
In normal skin, PCNA immunostaining was restricted to cells within the epidermis and sweat glands ((a,b) arrows). In two out of ten dcSSc samples, 
PCNA was detected in fibroblastic cells ((b) arrows) and in microvessels ((c) arrows). Double immunofluorescence labelling of dcSSc skin: cryosec-
tions were double stained with a combination of antibodies against (d,e) PCNA and α -SMA and (f) PCNA and PAL-E. PCNA is labelled with Texas 
Red while α -SMA and PAL-E are labelled with FITC. Colocalization was detected with PCNA and α -SMA antibodies within the microvasculature 
((d,e) arrows, yellow colour). When used in combination with PAL-E, PCNA-labelled cells ((f) arrows) were predominantly located adjacent and ablu-
minal to endothelial cells ((f) arrowheads). Original magnification × 20. α -SMA, alpha smooth muscle actin; dcSSc, diffuse cutaneous systemic scle-
rosis; PCNA, proliferating cell nuclear antigen; FITC, fluorescein isothiocyanate.
Table 2
Correlation of immunohistochemical and clinical data
Duration (months) Skin score Capillary pattern Collagen synthesis Myofibroblasts
Patient 1 4 19 L - +++
Patient 2 6 24 A +++ +
Patient 3 7 41 A - +++
Patient 4 9 38 N/D - +++
Patient 5 9 39 N/D +++ +++
Patient 6 10 34 A - +++
Patient 7 11 40 L +++ -
Patient 8 14 36 L - -
Patient 9 18 32 L - -
Patient 10 18 32 L +++ +++
Immunohistochemistry is quantified as; -, absent, +, weak, +++, strong. Patterns of capillary damage are graded as A, active, L, late or N/D, not 
determined.Available online http://arthritis-research.com/content/7/5/R1113
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samples contained both myofibroblasts and collagen-synthe-
sizing cells. This corroborates two recent studies of murine
lung fibrosis in which collagen-synthesizing cells were found
to be distinct from α -SMA+ve myofibroblasts [42,43] and a pre-
vious analysis of dcSSc skin, in which the presence of myofi-
broblasts did not correlate with α 1(I) procollagen mRNA [14].
The relationship between myofibroblasts and the synthesis
and deposition of fibrillar collagens is unknown and merits fur-
ther investigation. Myofibroblasts and ED-A FN were not
detected in skin taken from patients with atrophic dcSSc indi-
cating that, as the disease progresses from the fibrotic to
atrophic stage, myofibroblasts do not persist in the dermis.
Having recently been identified as a marker for cells with
myofibroblastic potential, we also analysed the distribution of
the Thy-1 antigen [18]. Two populations of Thy-1+ve cells were
identified in normal skin. Using double immunofluorescence
labelling, we identified one population as pericytes, the sec-
ond population, which was α -SMA-ve and located interstitially,
was identified as perivascular fibroblasts. In all dcSSc sam-
ples, Thy-1 was also found to be expressed by pericytes, how-
ever, there was a marked increase in Thy-1 immunostaining
throughout the interstitium. Using double immunofluorescence
labelling with α -SMA and ED-A FN antibodies, a number of the
interstitial Thy-1+ve  cells were identified as myofibroblasts
within the reticular dermis. However, Thy-1+ve /EDA-ve /SMA-ve
cells were also detected in the papillary dermis, suggesting
that the Thy-1+ve population can be divided into myofibroblas-
tic and non-myofibroblastic populations depending on their
location within the dermis.
Having demonstrated that in dcSSc skin, pericytes and myofi-
broblasts have an identical phenotype with respect to Thy-1,
ED-A FN and α -SMA expression, we then hypothesized that a
proliferation of pericytes may be in part responsible for the
expansion of pericytes and generation of myofibroblasts in the
interstitium. We found evidence of pericyte proliferation in two
dcSSc cases containing myofibroblasts suggesting that any
proliferative activity may be relatively short-lived. Increased
pericyte proliferation and an increased pericyte to endothelial
cell ratio have been recently reported in dcSSc skin [44] while
in keloid skin, evidence of pericyte differentiation has also
been observed [45]. Increased pericyte proliferation without a
corresponding increase in capillary density has also been
demonstrated in an in vivo tumour model and was found to be
mediated by PDGF-β  receptors [46]. PDGF is a potent
mitogen and we have previously demonstrated that microvas-
cular pericytes express PDGF-β  receptors in dcSSc skin [4]
suggesting that the observed pericyte proliferation in dcSSc
skin may be in part mediated by the PDGF-β  ligand/receptor
axis. Our findings lead us to propose a hypothesis that would
provide a cellular mechanism in dcSSc whereby initial microv-
ascular damage could give rise to a fibrotic lesion through the
increased production of ED-A FN by pericytes and
perivascular fibroblasts, which, in concert with other factors
Figure 7
Nailfold capillaroscopy of (a) normal and (b,c) dcSSc patients Nailfold capillaroscopy of (a) normal and (b,c) dcSSc patients. In the 
active pattern of capillary damage, frequent giant capillaries are present 
((b) arrow) accompanied by moderate capillary loss and disorganisation 
of capillary architecture. Late disease pattern was characterized by 
severe capillary disorganisation with loss of capillaries ((c) arrow). Mag-
nification ×150. dcSSc, diffuse cutaneous systemic sclerosis.Arthritis Research & Therapy    Vol 7 No 5    Rajkumar et al.
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(most notably TGF-β ) would promote the differentiation of
these cells into myofibroblasts (Fig. 8).
Conclusion
We believe there is strong evidence to suggest that pericytes
and myofibroblasts can be phenotypically linked by their
mutual synthesis of ED-A FN in dcSSc and that this may rep-
resent an important pathway in the transition of a
microvascular disease to a fibrotic one. We also suggest that
pericytes represent an additional cell type that must be taken
into account when considering pathogenic mechanisms and
therapeutic targets in dcSSc.
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